BCB-276

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameBCB-276
Drug Alias NameSCRI-CARB7H3SCRI-CARB7H3(s)BRAINCHILD-03BCB-276
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vector
Mechanisms of ActionT lymphocyte replacementsCD276 antigen inhibitors
TargetsCD276 antigen
Therapy Area/IndicationsSolid tumoursCentral Nervous System NeoplasmsCarcinoma +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBrainChild Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesSeattle Children'S Hospital
Inactive CompaniesN/A
Active IndicationsSolid tumoursCentral Nervous System NeoplasmsCarcinoma +[19] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A